Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1–2 years of treatment. We previously identified the most common mechanism of acquired resistance in HGSOC to date, transcripti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2021-11, Vol.13 (22), p.5644
Hauptverfasser:	Pishas, Kathleen I., Cowley, Karla J., Pandey, Ahwan, Hoang, Therese, Beach, Jessica A., Luu, Jennii, Vary, Robert, Smith, Lorey K., Shembrey, Carolyn E., Rashoo, Nineveh, White, Madelynne O., Simpson, Kaylene J., Bild, Andrea, Griffiths, Jason I., Cheasley, Dane, Campbell, Ian, Bowtell, David D. L., Christie, Elizabeth L.
Format:	Artikel
Sprache:	eng
Schlagworte:	ABC transporters Actin Biology Cancer therapies Cell culture Cell fusion Chemotherapy Cisplatin Cloning Cytology Cytotoxicity Doxorubicin Drug resistance Drug screening Extracellular matrix High-throughput screening Inflammation Kinases Metabolomics Multidrug resistance Mutation Ovarian cancer Oxidative metabolism Paclitaxel Patients Plasmids Proteins Reproductive system Transcription Tumorigenesis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!